摘要:
Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds.
摘要:
Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.
摘要:
The present invention provides a locking method and system, and the method includes: a locking system performing a phase discrimination and conversion process to an input signal Fi of an external standard source and a feedback output signal F0 of a local thermostatic crystal oscillator which pass through a frequency division, to generate a clock signal clk and a signal sign which is used to denote a frequency size relationship between the signal Fi and the signal F0, and performing a filtering process to the signal clk and the signal sign, and performing a voltage controlled oscillation process to a signal ahead used to denote that the frequency of the signal F0 is lower than the frequency of the signal Fi and a signal lag used to denote that the frequency of the signal F0 is higher than the frequency of the signal Fi, to implement a locking of the signal F0 and the signal Fi.
摘要:
The present invention provides a locking method and system, and the method includes: a locking system performing a phase discrimination and conversion process to an input signal Fi of an external standard source and a feedback output signal F0 of a local thermostatic crystal oscillator which pass through a frequency division, to generate a clock signal clk and a signal sign which is used to denote a frequency size relationship between the signal Fi and the signal F0, and performing a filtering process to the signal clk and the signal sign, and performing a voltage controlled oscillation process to a signal ahead used to denote that the frequency of the signal F0 is lower than the frequency of the signal Fi and a signal lag used to denote that the frequency of the signal F0 is higher than the frequency of the signal Fi, to implement a locking of the signal F0 and the signal Fi.
摘要:
Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.
摘要:
Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds.